Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd Internat...
September 28 2017 - 8:30AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that the Company will
present data from the Catabasis and Sarepta joint research
collaboration in Duchenne muscular dystrophy (DMD) at the 22nd
International Congress of the World Muscle Society in a poster
presentation titled “Edasalonexent (CAT-1004), an NF-kB inhibitor,
enhances myotube formation in vitro, and increases exon-skipped
sarcolemmal dystrophin in muscle of mdx mice” during poster session
4 on Thursday, October 5, 2017 from 17:00 – 18:30 CEST. The
International Congress of the World Muscle Society is being held
October 3 – 7, 2017, at the Palais du Grand Large in Saint Malo,
France.
About EdasalonexentEdasalonexent (CAT-1004) is an
investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by
DMD, regardless of their underlying mutation. Edasalonexent
inhibits NF-kB, a protein that is activated in DMD and drives
inflammation and fibrosis, muscle degeneration and suppresses
muscle regeneration. We are currently conducting the MoveDMD trial,
a three-part clinical trial investigating the safety and efficacy
of edasalonexent in boys enrolled at ages 4 – 7 affected with DMD
(any confirmed mutation). The third part of the trial, an
open-label extension with edasalonexent, is ongoing. The FDA has
granted orphan drug, fast track and rare pediatric disease
designations and the European Commission has granted orphan
medicinal product designation to edasalonexent for the treatment of
DMD. For a summary of clinical results reported to-date, please
visit www.catabasis.com.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted)
Linker drug discovery platform enables us to engineer molecules
that simultaneously modulate multiple targets in a disease. We are
applying our SMART LinkerSM platform to build an internal pipeline
of product candidates for rare diseases and plan to pursue
partnerships to develop additional product candidates. For more
information on the Company's drug discovery platform and pipeline
of drug candidates, please visit www.catabasis.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170928005295/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2024 to May 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From May 2023 to May 2024